Please try another search
INOVIQ Ltd is an Australia-based company, which is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. The Company’s cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.
Name | Age | Since | Title |
---|---|---|---|
Philip John Powell | 66 | 2019 | Independent Non-Executive Director |
Samuel Janes | - | 2017 | Member of Advisory Board |
Robert Maxwell Johnston | - | 2019 | Independent Non-Executive Director |
Geoffrey J. Cumming | - | 2020 | Independent Non-Executive Director |
David John Williams | 59 | 2023 | Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review